Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRVO Stock Forecast 2025-2026
$7.15
Current Price
$65.10M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRVO Price Targets
+193.7%
To High Target of $21.00
+109.8%
To Median Target of $15.00
+39.9%
To Low Target of $10.00
CRVO Price Momentum
+26.5%
1 Week Change
+0.4%
1 Month Change
-55.2%
1 Year Change
+205.6%
Year-to-Date Change
-65.3%
From 52W High of $20.63
+297.2%
From 52W Low of $1.80
📊 TOP ANALYST CALLS
Did CRVO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cervomed is one of their latest high-conviction picks.
Latest CRVO Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, CRVO has a bullish consensus with a median price target of $15.00 (ranging from $10.00 to $21.00). Currently trading at $7.15, the median forecast implies a 109.8% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sumant Kulkarni at Canaccord Genuity, projecting a 193.7% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 39.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRVO Analyst Ratings
6
Buy
0
Hold
0
Sell
CRVO Price Target Range
Low
$10.00
Average
$15.00
High
$21.00
Current: $7.15
Latest CRVO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRVO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| May 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| May 12, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $15.00 |
| Mar 26, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 18, 2025 | Roth MKM | Boobalan Pachaiyappan | Buy | Maintains | $20.00 |
| Mar 18, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $14.00 |
| Mar 18, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $21.00 |
| Mar 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 13, 2025 | Jones Trading | Soumit Roy | Buy | Upgrade | $15.00 |
| Mar 13, 2025 | Chardan Capital | Daniil Gataulin | Buy | Upgrade | $14.00 |
| Mar 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 11, 2025 | Roth MKM | Boobalan Pachaiyappan | Buy | Maintains | $15.00 |
| Feb 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Upgrade | $10.00 |
| Dec 17, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Downgrade | $0.00 |
| Dec 11, 2024 | Chardan Capital | Daniil Gataulin | Neutral | Downgrade | $0.00 |
| Dec 11, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $12.00 |
| Dec 10, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $0.00 |
| Dec 10, 2024 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $0.00 |
| Dec 5, 2024 | Roth MKM | Boobalan Pachaiyappan | Buy | Initiates | $45.00 |
| Dec 5, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $42.00 |
CervoMed Inc. (CRVO) Competitors
The following stocks are similar to Cervomed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CervoMed Inc. (CRVO) Financial Data
CervoMed Inc. has a market capitalization of $65.10M with a P/E ratio of 4.9x. The company generates $9.31M in trailing twelve-month revenue with a -200.6% profit margin.
Revenue growth is -18.3% quarter-over-quarter, while maintaining an operating margin of -276.6% and return on equity of -93.4%.
Valuation Metrics
Market Cap
$65.10M
Enterprise Value
$19.45M
P/E Ratio
4.9x
PEG Ratio
-2.9x
Price/Sales
7.0x
Growth & Margins
Revenue Growth (YoY)
-18.3%
Gross Margin
N/A
Operating Margin
-276.6%
Net Margin
-200.6%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+56.6%
Current Ratio
9.8x
Debt/Equity
0.0x
ROE
-93.4%
ROA
-56.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CervoMed Inc. (CRVO) Business Model
About CervoMed Inc.
What They Do
Develops treatments for neurodegenerative diseases.
Business Model
CervoMed Inc. generates revenue through the research and development of innovative therapies for conditions like Alzheimer's and Parkinson's disease. The company partners with academic institutions, healthcare providers, and industry players to enhance its research capabilities and accelerate the development of effective treatments, which may lead to licensing agreements or product sales in the future.
Additional Information
CervoMed is recognized for its scientific expertise in neurotherapeutics, focusing on breakthrough solutions in a highly specialized biotech sector. Its commitment to improving patient outcomes positions it as a critical player in advancing medical research for debilitating neurological disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Dr. John J. Alam M.D.
Country
United States
IPO Year
2023
Website
www.cervomed.comCervoMed Inc. (CRVO) Latest News & Analysis
Latest News
Quick Summary
CervoMed Inc. (NASDAQ: CRVO) will present findings from its Phase 2b study on neflamapimod for dementia with Lewy bodies at the Alzheimer's Association International Congress from July 27-31, 2025.
Why It Matters
CervoMed's upcoming presentations at a major Alzheimer's conference highlight potential breakthroughs in dementia treatment, which could significantly impact its stock value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Positive results from the 16-week extension phase of the Phase 2b RewinD-LB trial suggest neflamapimod may be a viable treatment for dementia with Lewy bodies (DLB).
Why It Matters
Positive trial results for neflamapimod suggest a potential new treatment for dementia with Lewy bodies, which could lead to increased market interest and potential revenue for the developing company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CervoMed Inc. (CRVO) reported a quarterly loss of $0.56 per share, better than the expected loss of $0.60, but wider than the $0.41 loss per share from the previous year.
Why It Matters
CervoMed's smaller-than-expected loss may indicate improving financial health, potentially boosting investor confidence despite year-over-year losses.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
CervoMed Inc. rose over 300% in Q1 2025 following positive Phase 2b trial results for neflamapimod. Chimerix Inc. increased 144% due to its acquisition by Jazz Pharmaceuticals and positive FDA feedback.
Why It Matters
Recent biotech stock surges highlight potential for high returns amid risk. Positive trial results and acquisitions can significantly boost stock value, influencing investment strategies.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
CervoMed Inc. (NASDAQ: CRVO) will present findings from its RewinD-LB Phase 2b study on neflamapimod for dementia with Lewy bodies at the AP/PD Conference in Vienna from April 1-5, 2025.
Why It Matters
CervoMed's presentation at a major conference highlights potential advancements in treatment for dementia, which could drive investor interest and affect stock performance based on study results.
Source: GlobeNewsWire
Market Sentiment:
Neutral
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
3 months ago
Quick Summary
CervoMed's stock rose over 400% following positive interim data for neflamapimod in treating Dementia with Lewy Bodies. The company is funded through 2026 but may require additional funds for further trials.
Why It Matters
CervoMed's stock spike reflects strong investor interest in its dementia treatment, but concerns over data validity and future funding needs may impact long-term confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CRVO Stock
What is CervoMed Inc.'s (CRVO) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, CervoMed Inc. (CRVO) has a median price target of $15.00. The highest price target is $21.00 and the lowest is $10.00.
Is CRVO stock a good investment in 2026?
According to current analyst ratings, CRVO has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRVO stock?
Wall Street analysts predict CRVO stock could reach $15.00 in the next 12 months. This represents a 109.8% increase from the current price of $7.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CervoMed Inc.'s business model?
CervoMed Inc. generates revenue through the research and development of innovative therapies for conditions like Alzheimer's and Parkinson's disease. The company partners with academic institutions, healthcare providers, and industry players to enhance its research capabilities and accelerate the development of effective treatments, which may lead to licensing agreements or product sales in the future.
What is the highest forecasted price for CRVO CervoMed Inc.?
The highest price target for CRVO is $21.00 from Sumant Kulkarni at Canaccord Genuity, which represents a 193.7% increase from the current price of $7.15.
What is the lowest forecasted price for CRVO CervoMed Inc.?
The lowest price target for CRVO is $10.00 from Jason Kolbert at D. Boral Capital, which represents a 39.9% increase from the current price of $7.15.
What is the overall CRVO consensus from analysts for CervoMed Inc.?
The overall analyst consensus for CRVO is bullish. Out of 10 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are CRVO stock price projections?
Stock price projections, including those for CervoMed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 1:34 PM UTC